Choongwae seeks approval for new quinolone
Choongwae Pharmaceutical of Korea has said it plans to ask thatcountry's Food and Drug Administration for approval to market its new quinolone antibiotic, Q-35, before the end of July. The company completed its Phase III testing program for the drug in January, according to a report on the Yonhap News Service.
Choongwae hopes to launch the product in Korea at the beginning of next year for the initial indication of urinary tract infections and cystitis.
Choongwae has also announced plans to forge joint-venture agreements with Monomedi and Missda of Malaysia, as well as Dapharco of Vietnam, according to the Asia Pulse News Service. All the JVs will be based in Vietnam and will manufacture intravenous solutions and infusion sets. Meanwhile, Choongwae said it will build a new manufacturing facility in Danang as part of its expansion activities in Vietnam.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze